Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
Clinical trial NCT03085758 · COMPLETED
Trial details
- NCT number
- NCT03085758
- Sponsor
- Adrenomed AG
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-12
- Primary completion
- 2019-12-20
- Enrollment
- 301
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.